Composite thromboembolic event end point rates in IVIg user and nonuser groups over 1 year of follow-up
| IVIg exposure . | Person-years . | Event rate per 100 person-years . | HR* (95% CI) . |
|---|---|---|---|
| Nonusers (n = 8035) | 3314.1 | 3.38 | 1.00 (ref) |
| IVIg new users (n = 2724) by recency of IVIg exposure | |||
| Days 0-30 | 872.9 | 4.58 | 1.36 (0.95, 1.96) |
| Days 00-01 | 66.6 | 7.51 | 2.26 (0.87, 5.90) |
| Days 02-15 | 428.8 | 4.90 | 1.50 (0.92, 2.44) |
| Days 16-30 | 377.6 | 3.71 | 1.06 (0.61, 1.87) |
| Days 31-90 | 388.0 | 4.90 | 1.50 (0.91, 2.45) |
| Indeterminate | 13.2 | 7.55 | † |
| IVIg exposure . | Person-years . | Event rate per 100 person-years . | HR* (95% CI) . |
|---|---|---|---|
| Nonusers (n = 8035) | 3314.1 | 3.38 | 1.00 (ref) |
| IVIg new users (n = 2724) by recency of IVIg exposure | |||
| Days 0-30 | 872.9 | 4.58 | 1.36 (0.95, 1.96) |
| Days 00-01 | 66.6 | 7.51 | 2.26 (0.87, 5.90) |
| Days 02-15 | 428.8 | 4.90 | 1.50 (0.92, 2.44) |
| Days 16-30 | 377.6 | 3.71 | 1.06 (0.61, 1.87) |
| Days 31-90 | 388.0 | 4.90 | 1.50 (0.91, 2.45) |
| Indeterminate | 13.2 | 7.55 | † |